Therapeutic area expertise, right where you need us
In today’s pressure-filled clinical trial environment, there is no substitute for knowledge and experience. Therapeutic area expertise is particularly important as biopharmaceutical companies develop new classes of compounds such as biologics and gene therapies that target complex and difficult diseases. PAREXEL's medical directors, physicians, and scientists have extensive experience in all major therapeutic areas. These experts are available right where you need them, at every stage of the clinical development process: clinical pharmacology; early-phase studies; pivotal trial planning and design; protocol development; site selection; data analysis; and regulatory submissions. Our therapeutic area expertise is essential to designing cost-effective clinical trials that deliver the data you need to support your novel therapies.
PAREXEL’s therapeutic area knowledge extends to the array of sophisticated technologies that are playing an increasingly important role in drug development, such as biomarkers and medical imaging. Our technology subsidiary, Perceptive Informatics, is a world leader in medical imaging technology, with in-house experts on the application of the right technologies for specific therapeutic areas.
Four key areas in which we have extensive therapeutic expertise are cardiovascular/metabolic diseases, central nervous system (CNS) disorders, infectious diseases, and oncology/hematology. We offer broad study experience and direct knowledge of study requirements, risk management, and best practices implementation in these key therapeutic areas. Other important areas of PAREXEL's therapeutic expertise include:
- Allergy/Immunology
- Orthopedics
- Anesthesia
- Otolaryngology
- Dentistry
- Pediatrics
- Dermatology
- Podiatry
- Endocrine/Metabolism
- Psychiatry
- Gastroenterology
- Pulmonology
- Genitourinary
- Radiology
- Gerontology
- Rheumatology
- Hematology
- Transplant
- Obstetrics/Gynecology
- Veterinary
- Ophthalmology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|



